Phio Pharmaceuticals Corp. · NASDAQ:PHIO
Phio Pharmaceuticals — RXi Pharmaceuticals — IPO Roadshow (September 2018)
19 slides from Phio Pharmaceuticals's IPO roadshow presentation, Sep 14, 2018
Slide 1: Developing the Next Generation of Immuno-Oncology Therapeutics
Property of RXi Pharmaceuticals RXi Pharmaceuticals NASDAQ: RXII www.rxipharma.com Developing the Next Generation of Immuno - Oncology Therapeutics Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated September 14, 2018 Relating to Prospectus dated September 14, 2018 Registration Statemen
Slide 2: Forward Looking Statements
Property of RXi Pharmaceuticals Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “s
Slide 3: Regulatory and Clinically Validated Technology Supports Development Strategy
Property of RXi Pharmaceuticals 3 Regulatory and Clinically Validated Technology Supports Development Strategy Developing the Next Generation of RNAi - based Immuno - Oncology Therapeutics using sd - rxRNA FDA approved new class of RNAi - based therapeutics sd - rxRNA proven safe and effective in P2
Slide 4: Cancer: A Large Unmet Need
Property of RXi Pharmaceuticals 4 Cancer: A Large Unmet Need U.S. Statistics at a Glance *https://seer.cancer.gov/statfacts/html/all.html Estimated number of new cases of cancer in 2018 Estimated number of cancer deaths in 2018 1,735,350 609,640 Solid tumors ~1.6M Hematological ~135K Solid tumors ~5
Slide 5: New Therapies Provide Patients and Physicians More Options to Overcome Cancer
Property of RXi Pharmaceuticals New Therapies Provide Patients and Physicians More Options to Overcome Cancer Figure adapted from: Baselga J., et al. , Clin Cancer Res October 1 2015 (21) (19 Supplement) S1 - S128; DOI: 10.1158/1078 - 0432.CCR - 15 - 1846 Radiotherapy Surgery Traditional Chemotherap
Slide 6: Immuno-Oncology Therapeutics Powerful Method to Destroy Tumor Cells
Property of RXi Pharmaceuticals Immuno - Oncology Therapeutics Powerful Method to Destroy Tumor Cells Immunotherapies harness our immune system to restore surveillance of evaded tumors – a potential curative medicine Cancer immunotherapy: Target the reasons why cancer develops. This can be done by r
Slide 7: Filling the Unmet Need of Other Therapeutic Approaches
Property of RXi Pharmaceuticals sd - rxRNA: Filling the Unmet Need of Other Therapeutic Approaches Advantages of Self - Delivering RNAi Therapeutic Platform sd - rxRNA ® • Can address intra - and extra - cellular targets • Target multiple protein targets alone or in combination • Fast lead generatio
Slide 8: Strategy to Tackle Different Immune Escape Mechanisms to Treat Solid Tumors
Property of RXi Pharmaceuticals Strategy to Tackle Different Immune Escape Mechanisms to Treat Solid Tumors Adoptive Cell Transfer (ACT) T Cells and Checkpoints Other Targets with ACT Direct Tumor Injections Checkpoint Inhibition “Release breaks” Cell Exhaustion / Persistence “Improve engine and fue
Slide 9: Pipeline of Therapeutic Development for Immuno-Oncology Therapeutics
Property of RXi Pharmaceuticals TREATMENT INDICATION DISCOVERY PRE - IND CLINICAL Melanoma Ovarian Cancer Head & Neck Other Various Various Various Various Melanoma Various Various Pipeline of Therapeutic Development for Immuno - Oncology Therapeutics Checkpoint Inhibition in ACT (TILs) RXI - 762 Ce
Slide 10: Immunotherapy to Treat Solid Tumors in Adoptive Cell Therapy (ACT)
Property of RXi Pharmaceuticals sd - rxRNA in Adoptive Cell Therapy (ACT) Immunotherapy to Treat Solid Tumors 1 2 3 RXi adds an important step in the ACT process. Pre - treatment of cells with sd - rxRNA compounds can be used to silence one or more immuno - suppressive genes (such as PD - 1 and othe
Slide 11: De-risked to Rapidly Advance to Clinical Development in Immuno-Oncology
Property of RXi Pharmaceuticals sd - rxRNA De - risked to Rapidly Advance to Clinical Development in Immuno - Oncology 11 sd - rxRNA platform clinically validated (safety and efficacy) in P2 trials by direct local injection Clinically validated targets in development for oncology Industry and academ
Slide 12: Collaboration Update – Checkpoint Inhibition
Property of RXi Pharmaceuticals • Background : Academic collaboration to determine feasibility of sd - rxRNA platform to enhance the function of TILs • Goal: Evaluate sd - rxRNA compounds targeting immune checkpoints in preclinical screening models of matched TIL/tumor cell pairs from melanoma and o
Slide 13: Reduction of PD1 Surface Levels in T Cells Treated with RXI-762
Property of RXi Pharmaceuticals Observe significant reduction of PD1 surface Levels in Activated T - cells (non - engineered) treated with RXI - 762 (72 and 96 hrs) 48 hrs post reactivation MFI Untransduced T cells TCR - 1 (T cells) TCR - 2 (T cells) Transduced Re - activated T Cells Observe reducti
Slide 14: Melanoma Collaboration Update – Intratumoral Injection
Property of RXi Pharmaceuticals • Background: Academic collaboration to determine feasibility of sd - rxRNA platform to target TME via intra - tumoral injection • Goal: Identify sd - rxRNA compounds to Gustave Roussy’s target of interest and demonstrate efficacy (silencing and phenotypic effect) of
Slide 15: Clinical Development Path
Property of RXi Pharmaceuticals 15 Clinical Development Path: 12 - 18 Months - - INDICATION Preclinical data available to support selection of target indication PHENOTYPIC DATA In - vitro efficacy and safety data available for regulatory submission STUDY START Approval received for first patient dos
Slide 16: Powerful Therapeutic Platform
Property of RXi Pharmaceuticals sd - rxRNA: Powerful Therapeutic Platform 16
Slide 17: Broad Intellectual Property Position in RNAi Compounds and Delivery
Property of RXi Pharmaceuticals Broad Intellectual Property Position in RNAi Compounds and Delivery 17 sd - rxRNA: Freedom to Operate 1 3 9 15 17 19 21 23 25 27 6 13 16 20 22 24 26 28 29 2 4 5 7 8 10 11 12 14 30 18 RNA Duplex Length sd - rxRNA Conventional siRNA rxRNAori dsRNA Kreutzer - Limmer sd -
Slide 18: Financial Overview
Property of RXi Pharmaceuticals Financial Overview Cash and cash equivalents* ~$4.0M Burn rate ~$2.0M/quarter Cash runway Q1 2019 Cash runway (Assuming full use of $15M equity line available) Q2 2020 Common shares outstanding ~4.4M Market Cap ~$6.8M *Unaudited 18 As of 08/30/2018
Slide 19: Future Milestones
Property of RXi Pharmaceuticals 19 Future Milestones BD transaction for dermatology and ophthalmology franchises Data from internal studies and external collaborations Advance regulatory document for IND / IMPD submission Increase number of collaborations to develop new immunotherapies to treat canc